GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for ...

Getting to grips with rising diabetes rates is arguably one of the most urgent tasks for South Africa's public healthcare system, but the setbacks keep coming. While some communities are facing ...

Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

Despite its small base, rapid growth in smart insulin administration, connected devices, patient-centric care, and home-based ...

The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...

About valuation, the current forward P/E is 13, but that number only looks cheap because earnings are at an unsustainably ...

The company that sells Ozempic and Wegovy, drugs known for promoting easy weight loss, is now selling the products at Costco.

Pill versions of the obesity drugs now taken only as injections are on the way. We look at the science behind the pills and if they might be more affordable and accessible than the shots.

Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, becoming the first publicly ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...

Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease ...